HSK39004 Dry Powder Inhaler -0.75mg BID
Sponsors
Haisco Pharmaceutical Group Co., Ltd.
Conditions
Chronic Obstructive Lung Disease (COLD)
Phase 2
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
RecruitingNCT07140328
Start: 2025-04-24End: 2026-08-01Target: 50Updated: 2026-06-09
Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD
Not yet recruitingNCT07425210
Start: 2026-03-01End: 2027-08-01Target: 300Updated: 2026-02-25